Why Is SciSparc (SPRC) Stock Up 25% Today?

Investorplace·07/16/2024 14:43:11

Listen to the news

SciSparc notes that this patent covers the company’s collaboration with Clearmind Medicine (NASDAQ:CMND). This is a clinical-stage biotech company focused on psychedelic-derived therapeutics.

This patent covers the novel proprietary composition of Palmitoylethanolamide. This is the active ingredient in SciSparc’s proprietary CannAmide. It’s used alongside Clearmind Medicine’s MEAI compound to treat metabolic syndrome and obesity.

Here’s what SpcSparc had to say about the new patent.

“Overall, as part of this collaboration, twelve other patent applications have been filed by Clearmind with the USPTO for various compositions, including the proprietary composition of SciSparc's PEA with Clearmind's MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.”

What This Means for SPRC Stock

SciSparc could reach a large market with its obesity treatment. The Centers for Disease Control and Prevention (CDC) estimates that 41.9% of adults over the age of 20 are obese. This saw the market reach $15 billion in 2022.

SPRC stock is up 24.6% as of Tuesday morning. This comes with some 37 million shares traded. That’s well above its daily average trading volume of about 138,000 shares.

Investors will want to stick around for more of the most recent stock market stories today!

We have all of the hottest stock market news traders need to know about on Tuesday! Among that is what has shares of Match Group (NASDAQ:MTCH), Greenpro Capital (NASDAQ:GRNQ) and Autonomix Medical (NASDAQ:AMIX) stock moving today. You can read all about that at the links below!

More Tuesday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

More From InvestorPlace

Legendary Investor Predicts: "Forget A.I. THIS Technology Is the Future"

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English